Posted by Michael Wonder on 21 Mar 2017
Sanofi, CVS, others accused of insulin price fixing
21 March 2017 - The leading U.S. drugmakers and pharmacy benefit managers colluded to fix prices for insulin, leading to skyrocketing costs and windfall profits for the companies, a new lawsuit alleges.
Some of the biggest players in the American health-care industry are targeted in the 69-count class action complaint, filed March 17 in a federal court in New Jersey. Drug manufacturers Sanofi-Aventis, Novo Nordisk and Eli Lilly are included.
Also named are the country’s three largest pharmacy benefit managers—CVS Health, Express Scripts and OptumRx—which together control 80% of the PBM industry and manage benefits for 180 million people.
